详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Genotype-guided Treatment in Newly Diagnosed PTCL

7| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究负责人：

研究单位： [1]Ruijin hospital,Shanghai,Shanghai,China,200025 [2]The First Affiliated Hospital of Nanchang University [3]Peking University Third Hospital [4]Wuhan TongJi Hospital [5]West China Hospital [6]Nanfang Hospital, Southern Medical University [7]Anhui Provincial Cancer Hospital [8]The First Affiliated Hospital of Soochow University [9]The Second Affiliated Hospital of Harbin Medical University [10]The First Affiliated Hospital of Xiamen University [11]The First Affiliated Hospital of Zhengzhou University [12]Beijing Tongren Hospital [13]Peking University People's Hospital [14]Sun Yat-sen University [15]The First Affiliated Hospital of Anhui Medical University [16]The First Hospital of Jilin University

关键词： Biomarker-driven Genetic subtypes Complete response rate Phase 1/2 Precision medicine

研究目的：

This study includes Phase I and Phase II stages. Phase I is an open-label trial to confirm RP2D of oral targeted agents in three genetic subtypes. Phase II is a multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP-X2) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with peripheral T-cell lymphoma.